James Rolke
Chief Executive Officer en REVELATION BIOSCIENCES, INC. .
Fortuna: 1 858 $ al 31/03/2024
Perfil
James M.
Rolke is currently the Chief Executive Officer & Director at Revelation Biosciences Sub, Inc. and Revelation Biosciences, Inc. He is also a Director at Revelation Therapeutics LLC.
Previously, he held positions such as Associate Director-Pharmaceutical Development at Mersana Therapeutics, Operations Director at Prospect Therapeutics, Chief Scientific Officer at La Jolla Pharmaceutical Co., Manager-Process Development at Glycogenesys, and Chief Technology Officer at Pluromed, Inc. He also worked as an Associate Scientist at Alpha-Beta Technology, Inc., Principal Scientist at Surgical Sealants, Inc., and Scientist at Geltex, Inc. Mr. Rolke received his undergraduate degree from Keene State College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 18/03/2024 | 678 ( 0.04% ) | 1 858 $ | 31/03/2024 |
Cargos activos de James Rolke
| Empresas | Cargo | Inicio |
|---|---|---|
| REVELATION BIOSCIENCES, INC. | Chief Executive Officer | 01/05/2020 |
Revelation Therapeutics LLC
 Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | Director/Board Member | - |
Revelation Biosciences Sub, Inc.
 Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Chief Executive Officer | 01/05/2020 |
Antiguos cargos conocidos de James Rolke.
| Empresas | Cargo | Fin |
|---|---|---|
| LA JOLLA PHARMACEUTICAL COMPANY | Chief Tech/Sci/R&D Officer | 31/05/2020 |
Pluromed, Inc.
 Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Prospect Therapeutics, Inc.
 Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Corporate Officer/Principal | 01/01/2009 |
| MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2007 |
Glycogenesys, Inc.
 Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2006 |
Formación de James Rolke.
| Keene State College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| REVELATION BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 9 |
|---|---|
Alpha-Beta Technology, Inc.
 Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
Pluromed, Inc.
Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | Health Technology |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Health Technology |
| Surgical Sealants, Inc. | |
Revelation Therapeutics LLC
Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | Commercial Services |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Health Technology |
| Geltex, Inc. |
- Bolsa de valores
- Insiders
- James Rolke
